Replimune Group (REPL) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

REPL Stock Forecast

Replimune Group stock forecast is as follows: an average price target of $23.00 (represents a 63.47% upside from REPL’s last price of $14.07) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

REPL Price Target

The average price target for Replimune Group (REPL) is $23.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $27.00 to $19.00. This represents a potential 63.47% upside from REPL's last price of $14.07.

REPL Analyst Ratings

Buy

According to 7 Wall Street analysts, Replimune Group's rating consensus is 'Buy'. The analyst rating breakdown for REPL stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Replimune Group Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jan 22, 2025	Evan Seigerman	BMO Capital	$27.00	$13.09	106.26%	91.90%
Dec 03, 2024	Roger Song	Jefferies	$19.00	$14.48	31.22%	35.04%
Jun 07, 2024	Robert Burns	H.C. Wainwright	$17.00	$7.11	139.10%	20.82%
Jun 04, 2024	Peter Lawson	Barclays	$13.00	$5.37	142.09%	-7.60%
May 17, 2024	Evan Seigerman	BMO Capital	$14.00	$6.85	104.38%	-0.50%
Dec 12, 2022		BMO Capital	$70.00	$25.00	180.00%	397.51%
Dec 07, 2022		Leerink Partners	$34.00	$23.09	47.25%	141.65%
Oct 03, 2022		Leerink Partners	$30.00	$17.27	73.71%	113.22%
Aug 17, 2022		Piper Sandler	$43.00	$20.62	108.54%	205.61%
Aug 05, 2022		Leerink Partners	$37.00	$20.37	81.64%	162.97%
May 20, 2022		Leerink Partners	$48.00	$14.38	233.80%	241.15%

The latest Replimune Group stock forecast, released on Jan 22, 2025 by Evan Seigerman from BMO Capital, set a price target of $27.00, which represents a 106.26% increase from the stock price at the time of the forecast ($13.09), and a 91.90% increase from REPL last price ($14.07).

Replimune Group Price Target by Period

	1M	3M	12M
# Anlaysts	1	2	5
Avg Price Target	$27.00	$23.00	$18.00
Last Closing Price	$14.07	$14.07	$14.07
Upside/Downside	91.90%	63.47%	27.93%

In the current month, the average price target of Replimune Group stock is $27.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 91.90% increase as opposed to Replimune Group's last price of $14.07. This month's average price target is up 17.39% compared to last quarter, and up 50.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jan 22, 2025	BMO Capital	Outperform	Outperform	Hold
Dec 03, 2024	Jefferies	Buy	Buy	Hold
Nov 22, 2024	BMO Capital	Outperform	Outperform	Hold
Sep 10, 2024	BMO Capital	Outperform	Outperform	Hold
Sep 10, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 08, 2024	Rodman & Renshaw		Buy	Initialise
Jun 07, 2024	BMO Capital	Outperform	Outperform	Hold
Jun 07, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 04, 2024	Barclays	Overweight	Overweight	Hold
May 17, 2024	BMO Capital	Outperform	Outperform	Hold
Dec 06, 2023	Barclays	Overweight	Overweight	Hold
Dec 12, 2022	BMO Capital	Outperform	Outperform	Hold
Dec 07, 2022	SVB Leerink	Outperform	Outperform	Hold
Oct 03, 2022	SVB Leerink	Outperform	Outperform	Hold
Aug 17, 2022	Piper Sandler	Overweight	Overweight	Hold
Aug 05, 2022	SVB Leerink	Outperform	Outperform	Hold
May 20, 2022	SVB Leerink	Outperform	Outperform	Hold

Replimune Group's last stock rating was published by BMO Capital on Jan 22, 2025. The company gave REPL a "Outperform" rating, the same as its previous rate.

Replimune Group Financial Forecast

Replimune Group Revenue Forecast

	Sep 29	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$130.06M	$122.26M	$114.41M	$110.02M	$102.89M	$94.68M	$87.61M	$81.44M	$74.42M	$66.94M	$59.93M	$55.11M	$49.29M	$42.27M	$27.77M	$20.07M	$5.02M	$15.37M	$5.56M	-	-	-
High Forecast	$130.06M	$122.26M	$114.41M	$110.02M	$102.89M	$94.68M	$87.61M	$81.44M	$74.42M	$66.94M	$59.93M	$55.11M	$49.29M	$42.27M	$27.77M	$20.07M	$5.02M	$15.37M	$5.56M	-	-	-
Low Forecast	$130.06M	$122.26M	$114.41M	$110.02M	$102.89M	$94.68M	$87.61M	$81.44M	$74.42M	$66.94M	$59.93M	$55.11M	$49.29M	$42.27M	$27.77M	$20.07M	$5.02M	$15.37M	$5.56M	-	-	-
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Replimune Group's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. REPL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Replimune Group EBITDA Forecast

	Sep 29	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict REPL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Replimune Group's previous annual EBITDA (undefined) of $NaN.

Replimune Group Net Income Forecast

	Sep 29	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-2.60M	$-5.84M	$-9.11M	$-10.62M	$-13.55M	$-17.05M	$-19.97M	$-22.45M	$-25.37M	$-28.71M	$-34.71M	$-31.33M	$-29.82M	$-28.77M	$-49.06M	$-53.14M	$-56.68M	$-59.21M	$-56.72M	$-55.48M	$-64.69M	$-59.29M
High Forecast	$-2.60M	$-5.84M	$-9.11M	$-10.62M	$-13.55M	$-17.05M	$-19.97M	$-22.45M	$-25.37M	$-28.71M	$-34.71M	$-31.33M	$-29.82M	$-28.77M	$-49.06M	$-53.14M	$-56.68M	$-59.21M	$-54.25M	$-49.93M	$-64.69M	$-59.29M
Low Forecast	$-2.60M	$-5.84M	$-9.11M	$-10.62M	$-13.55M	$-17.05M	$-19.97M	$-22.45M	$-25.37M	$-28.71M	$-34.71M	$-31.33M	$-29.82M	$-28.77M	$-49.06M	$-53.14M	$-56.68M	$-59.21M	$-61.65M	$-57.86M	$-64.69M	$-59.29M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Replimune Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. REPL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Replimune Group SG&A Forecast

	Sep 29	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Replimune Group's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to REPL last annual SG&A of $NaN (undefined).

Replimune Group EPS Forecast

	Sep 29	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.03	$-0.07	$-0.12	$-0.14	$-0.17	$-0.22	$-0.25	$-0.29	$-0.32	$-0.37	$-0.44	$-0.40	$-0.38	$-0.37	$-0.62	$-0.68	$-0.72	$-0.75	$-0.72	$-0.71	$-0.82	$-0.86
High Forecast	$-0.03	$-0.07	$-0.12	$-0.14	$-0.17	$-0.22	$-0.25	$-0.29	$-0.32	$-0.37	$-0.44	$-0.40	$-0.38	$-0.37	$-0.62	$-0.68	$-0.72	$-0.75	$-0.69	$-0.64	$-0.82	$-0.86
Low Forecast	$-0.03	$-0.07	$-0.12	$-0.14	$-0.17	$-0.22	$-0.25	$-0.29	$-0.32	$-0.37	$-0.44	$-0.40	$-0.38	$-0.37	$-0.62	$-0.68	$-0.72	$-0.75	$-0.78	$-0.74	$-0.82	$-0.86
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Replimune Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to REPL previous annual EPS of $NaN (undefined).

Replimune Group Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.94	$33.86	1645.36%	Buy
KROS	Keros Therapeutics	$11.37	$101.00	788.30%	Buy
AVTE	Aerovate Therapeutics	$2.58	$13.00	403.88%	Hold
GOSS	Gossamer Bio	$0.92	$3.75	307.61%	Buy
PRTC	PureTech Health	$18.64	$57.00	205.79%	Buy
MLYS	Mineralys Therapeutics	$10.36	$30.00	189.58%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
KURA	Kura Oncology	$7.69	$19.00	147.07%	Buy
SNDX	Syndax Pharmaceuticals	$14.24	$30.60	114.89%	Buy
NAMS	NewAmsterdam Pharma	$20.78	$41.50	99.71%	Buy
MRUS	Merus	$41.65	$81.25	95.08%	Buy
CRNX	Crinetics Pharmaceuticals	$39.38	$69.00	75.22%	Buy
ASND	Ascendis Pharma	$127.55	$211.14	65.54%	Buy
REPL	Replimune Group	$14.07	$23.00	63.47%	Buy
PTGX	Protagonist Therapeutics	$38.21	$57.33	50.04%	Buy
NUVL	Nuvalent	$85.52	$114.80	34.24%	Buy
UTHR	United Therapeutics	$372.75	$458.00	22.87%	Buy
KRON	Kronos Bio	$1.02	$1.00	-1.96%	Buy

REPL Forecast FAQ

Is Replimune Group a good buy?

Yes, according to 7 Wall Street analysts, Replimune Group (REPL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of REPL's total ratings.

What is REPL's price target?

Replimune Group (REPL) average price target is $23 with a range of $19 to $27, implying a 63.47% from its last price of $14.07. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Replimune Group stock go up soon?

According to Wall Street analysts' prediction for REPL stock, the company can go up by 63.47% (from the last price of $14.07 to the average price target of $23), up by 91.90% based on the highest stock price target, and up by 35.04% based on the lowest stock price target.

Can Replimune Group stock reach $20?

REPL's average twelve months analyst stock price target of $23 supports the claim that Replimune Group can reach $20 in the near future.

What is Replimune Group's current price target trend?

1 Wall Street analyst forecast a $27 price target for Replimune Group (REPL) this month, up 91.90% from its last price of $14.07. Compared to the last 3 and 12 months, the average price target increased by 63.47% and increased by 27.93%, respectively.

What are Replimune Group's analysts' financial forecasts?

Replimune Group's analysts financial forecasts for the fiscal year (Mar 2028) are as follows: average revenue is $310.41M (high $310.41M, low $310.41M), average EBITDA is $0 (high $0, low $0), average net income is $-96.5M (high $-96.5M, low $-96.5M), average SG&A $0 (high $0, low $0), and average EPS is $-1.228 (high $-1.228, low $-1.228). REPL's analysts financial forecasts for the fiscal year (Mar 2029) are as follows: average revenue is $422.01M (high $422.01M, low $422.01M), average EBITDA is $0 (high $0, low $0), average net income is $-50.332M (high $-50.332M, low $-50.332M), average SG&A $0 (high $0, low $0), and average EPS is $-0.641 (high $-0.641, low $-0.641).